Erin Murphy, MD, discusses future research efforts with pazopanib plus stereotactic body radiation therapy in patients with pediatric sarcoma.
Erin Murphy, MD, a radiation oncologist at Cleveland Clinic, discusses future research efforts with pazopanib (Votrient) plus stereotactic body radiation therapy (SBRT) in patients with pediatric sarcoma.
It is necessary to take a closer look at the regimen to determine which factors may help to achieve local control vs failure, as well as to determine the optimal dose of SBRT, according to Murphy. Several patients with pediatric sarcoma included in single-institution retrospective reviews trend toward receiving the median dose of SBRT, which appears to be applied regardless of histology, Murphy explains. Determining histology-specific, patient-specific dosing is an area of active interest, Murphy says.
Future research efforts should be focused on how to best target sarcoma lesions, as well as to determine the best imaging to help guide treatment decisions, Murphy adds. Questions regarding how SBRT can be optimized and how to best follow patients who have received treatment still need to be addressed, Murphy concludes.